Carvajal Alejandra's Insider Trades & SAST Disclosures
Carvajal Alejandra's most recent trade in Mersana Therapeutics Inc was a trade of 243,750 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 15, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Carvajal Alejandra.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Mersana Therapeutics Inc | Alejandra Carvajal | SVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 243,750 | 243,750 | - | - | Stock Option (Right to Buy) | |
| Mersana Therapeutics Inc | Alejandra Carvajal | SVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 54,167 | 54,167 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Alejandra Carvajal | SVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2025 | 12,500 | 83,392 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Alejandra Carvajal | SVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2025 | 12,500 | 37,500 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Alejandra Carvajal | SVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 0.58 per share. | 15 Jan 2025 | 5,096 | 78,296 (0%) | 0% | 0.6 | 2,956 | Common Stock |
| Mersana Therapeutics Inc | Alejandra Carvajal | SVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2025 | 2,500 | 71,844 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Alejandra Carvajal | SVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2025 | 2,500 | 2,500 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Alejandra Carvajal | SVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 0.63 per share. | 14 Jan 2025 | 952 | 70,892 (0%) | 0% | 0.6 | 600 | Common Stock |
| Mersana Therapeutics Inc | Alejandra Carvajal | SVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2025 | 8,958 | 17,917 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Alejandra Carvajal | SVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2025 | 8,958 | 72,674 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Alejandra Carvajal | SVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 0.66 per share. | 13 Jan 2025 | 3,330 | 69,344 (0%) | 0% | 0.7 | 2,198 | Common Stock |
| Mersana Therapeutics Inc | Alejandra Carvajal | SVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2024 | 50,000 | 0 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Alejandra Carvajal | SVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2024 | 50,000 | 77,403 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Alejandra Carvajal | SVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 2.00 per share. | 01 Oct 2024 | 8,089 | 69,314 (0%) | 0% | 2 | 16,178 | Common Stock |
| Mersana Therapeutics Inc | Alejandra Carvajal | SVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 1.96 per share. | 01 Oct 2024 | 5,598 | 63,716 (0%) | 0% | 2.0 | 10,972 | Common Stock |
| Mersana Therapeutics Inc | Alejandra Carvajal | SVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2024 | 225,000 | 225,000 | - | - | Stock Option (Right to Buy) | |
| Mersana Therapeutics Inc | Carvajal Alejandra | SVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2024 | 50,000 | 50,000 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Carvajal Alejandra | SVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 8,958 | 29,284 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Carvajal Alejandra | SVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 8,958 | 26,875 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Alejandra Carvajal | SVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 2.71 per share. | 13 Jan 2024 | 4,381 | 27,403 (0%) | 0% | 2.7 | 11,873 | Common Stock |
| Mersana Therapeutics Inc | Carvajal Alejandra | SVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 2,500 | 5,000 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Alejandra Carvajal | SVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 2,500 | 31,784 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Alejandra Carvajal | SVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2023 | 13,250 | 24,270 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Alejandra Carvajal | SVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2023 | 13,250 | 0 | - | - | Restricted stock unit | |
| Mersana Therapeutics Inc | Alejandra Carvajal | SVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 3.89 per share. | 26 Apr 2023 | 3,944 | 20,326 (0%) | 0% | 3.9 | 15,342 | Common Stock |
| Mersana Therapeutics Inc | Alejandra Carvajal | SVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2023 | 161,250 | 161,250 | - | - | Stock option (right to buy) | |
| Mersana Therapeutics Inc | Alejandra Carvajal | SVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2023 | 35,833 | 35,833 | - | - | Restricted stock unit | |
| Mersana Therapeutics Inc | Alejandra Carvajal | SVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 2,500 | 11,802 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Alejandra Carvajal | SVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 2,500 | 7,500 | - | - | Restricted stock unit | |
| Mersana Therapeutics Inc | Alejandra Carvajal | SVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 5.74 per share. | 13 Jan 2023 | 782 | 11,020 (0%) | 0% | 5.7 | 4,489 | Common Stock |
| Mersana Therapeutics Inc | Alejandra Carvajal | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2022 | 13,250 | 13,250 | - | - | Restricted stock unit | |
| Mersana Therapeutics Inc | Alejandra Carvajal | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2022 | 13,250 | 13,250 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Alejandra Carvajal | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 3.69 per share. | 26 Apr 2022 | 3,948 | 9,302 (0%) | 0% | 3.7 | 14,568 | Common Stock |
| Mersana Therapeutics Inc | Alejandra Carvajal | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Mersana Therapeutics Inc | Alejandra Carvajal | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 10,000 | 10,000 | - | - | Restricted Stock Units | |
| Mersana Therapeutics Inc | Alejandra Carvajal | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Apr 2021 | 112,500 | 112,500 | - | - | Stock Option (right to buy) | |
| Mersana Therapeutics Inc | Alejandra Carvajal | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Apr 2021 | 26,500 | 25,000 | - | - | Restricted stock unit |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges